Clinical Trial: Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07836543) titled 'Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer' on Sept. 13.

Brief Summary: A randomized phase II study to assess the efficacy and safety of Trastuzumab Rezetecan and/or Adebrelimab as consolidation therapy following chemoradiotherapy in patients with unresectable stage III HER2-altered NSCLC.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Intervention: DRUG: Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab

Trastuzumab Rezetecan (4.8mg/kg, iv, d1, Q3W) and Adebrelimab (1200mg, iv, d1, Q3...